

**From:** Carl Olsen  
**To:** "[Hager, Kristi \[LEGIS\]](#)"  
**Subject:** RE: HSB 164  
**Date:** Tuesday, February 28, 2017 5:01:00 AM

---

Another issue is that the DEA moved hydrocodone "combination" products to schedule 2 in 2014 or maybe earlier. The board has been asking the legislature to reschedule it from schedule 3 in Iowa to schedule 2 since that time.

What harm has resulted?

None.

Doctors have to have both state and federal licenses, so hydrocodone combination products are effective in schedule 2 in Iowa unless Iowa moves them to schedule 1. The more severe of the two prevails, because doctors and pharmacists have to have both state and federal licenses to prescribe drugs.

So, you could put Epidiolex into schedule 2 today, or any schedule you want. You don't have to force the board to make a recommendation back to the legislature. You are the legislature.

HSB 159, HSB 164, and SF 282 make no sense.

We could do this for every pharmaceutical company from now on.

This pharmaceutical company is taking advantage of us and it should not get special treatment any more than any pharmaceutical company that comes out with a new drug.

The reason you see medical marijuana laws is because the government has never allowed research. Senator Grassley held hearings on this in 2015 where the Department of Health and Human Services admitted they have been blocking research.

Here's a January 2017 document from the National Academies of Science saying the same thing.

<https://www.nap.edu/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state>

Carl Olsen  
130 E Aurora Ave  
Des Moines, Iowa 50313-3654  
T 515-343-9933  
F 641-316-7358  
[carl-olsen@mchsi.com](mailto:carl-olsen@mchsi.com)  
<http://carl-olsen.com/>  
<http://iowamedicalmarijuana.org/>

---

**From:** Carl Olsen [mailto:carl-olsen@mchsi.com]  
**Sent:** Monday, February 27, 2017 8:47 PM  
**To:** 'Hager, Kristi [LEGIS]' <Kristi.Hager@legis.iowa.gov>  
**Subject:** RE: HSB 164

Kristi,

The only time the pharmacy board has not followed federal scheduling is when I sued them in 2009. They recommended reclassification of marijuana in 2010 after I sued them and won.

I see no reason to tell the board to reschedule a product approved by the FDA and the DEA. They do that all the time on a routine basis.

The board also uses emergency scheduling for extremely bad substances that the FDA and the DEA hasn't gotten around to scheduling. They never use emergency scheduling for a new FDA and DEA approved drug.

This pharmaceutical company is taking advantage of the situation. Every pharmaceutical company could make the same argument.

I am attaching some of the documents I am referencing, the court ruling, the board ruling, and the Iowa Supreme Court ruling.

Carl Olsen  
130 E Aurora Ave  
Des Moines, Iowa 50313-3654  
T 515-343-9933  
F 641-316-7358  
[carl-olsen@mchsi.com](mailto:carl-olsen@mchsi.com)  
<http://carl-olsen.com/>  
<http://iowamedicalmarijuana.org/>

---

**From:** Hager, Kristi [LEGIS] [<mailto:Kristi.Hager@legis.iowa.gov>]  
**Sent:** Monday, February 27, 2017 1:32 PM  
**To:** 'Carl Olsen' <[carl-olsen@mchsi.com](mailto:carl-olsen@mchsi.com)>  
**Subject:** RE: HSB 164

Carl, thank you. I appreciate the information and will check into this. Thanks again, Kristi

**Kristi Hager**  
State Representative  
*Fifty-sixth District*

Statehouse: (515) 281-7499  
Cell: (563) 568-1084  
Email: [kristi.hager@legis.iowa.gov](mailto:kristi.hager@legis.iowa.gov)  
*"Restore Iowa Back for the Future"*

---

**From:** Carl Olsen [<mailto:carl-olsen@mchsi.com>]  
**Sent:** Sunday, February 26, 2017 3:39 PM  
**To:** Hager, Kristi [LEGIS]  
**Subject:** HSB 164

130 E Aurora Ave  
Des Moines, IA 50313-3654  
February 26, 2017

Kristi Hager  
2026 Lycurgus Road  
Waukon, IA 52172

Dear Rep. Hager,

I am writing regarding HSB 164, an Act relating to the medical use of cannabidiol including the rescheduling of a cannabidiol investigational product approved as a prescription drug medication under federal law.

I believe it is unnecessary to instruct the Iowa Board of Pharmacy to schedule a product before it is known whether the product will be approved by the FDA and the DEA, and before it is known what schedule, if any, that product might be placed in by the FDA and the DEA.

I have asked the Iowa Board of Pharmacy to review SF 282, HSB 159, and HSB 164, at their next meeting on Wednesday, March 8, 2017. I am attaching my letters to the Iowa Board of Pharmacy for your review.

Please amend the bill by striking the language about federal scheduling.

Thank you!

Sincerely,

Carl Olsen  
515-343-9933  
[carl-olsen@mchsi.com](mailto:carl-olsen@mchsi.com)

Carl Olsen  
130 E Aurora Ave  
Des Moines, Iowa 50313-3654  
T 515-343-9933  
F 641-316-7358  
[carl-olsen@mchsi.com](mailto:carl-olsen@mchsi.com)  
<http://carl-olsen.com/>  
<http://iowamedicalmarijuana.org/>